200 related articles for article (PubMed ID: 38362864)
21. Alcohol, liver disease and the gut microbiota.
Bajaj JS
Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):235-246. PubMed ID: 30643227
[TBL] [Abstract][Full Text] [Related]
22. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.
Ezzaidi N; Zhang X; Coker OO; Yu J
Cancer Lett; 2019 Sep; 459():186-191. PubMed ID: 31185249
[TBL] [Abstract][Full Text] [Related]
23. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease.
Dubinkina VB; Tyakht AV; Odintsova VY; Yarygin KS; Kovarsky BA; Pavlenko AV; Ischenko DS; Popenko AS; Alexeev DG; Taraskina AY; Nasyrova RF; Krupitsky EM; Shalikiani NV; Bakulin IG; Shcherbakov PL; Skorodumova LO; Larin AK; Kostryukova ES; Abdulkhakov RA; Abdulkhakov SR; Malanin SY; Ismagilova RK; Grigoryeva TV; Ilina EN; Govorun VM
Microbiome; 2017 Oct; 5(1):141. PubMed ID: 29041989
[TBL] [Abstract][Full Text] [Related]
24. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans.
Maccioni L; Gao B; Leclercq S; Pirlot B; Horsmans Y; De Timary P; Leclercq I; Fouts D; Schnabl B; Stärkel P
Gut Microbes; 2020 Nov; 12(1):1782157. PubMed ID: 32588725
[TBL] [Abstract][Full Text] [Related]
25. Gut-Liver-Brain Axis and Alcohol Use Disorder: Treatment Potential of Fecal Microbiota Transplantation.
Wolstenholme JT; Duong NK; Brocato ER; Bajaj JS
Alcohol Res; 2024; 44(1):01. PubMed ID: 38322428
[TBL] [Abstract][Full Text] [Related]
26. Intestinal microbiota in liver disease.
Haque TR; Barritt AS
Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):133-42. PubMed ID: 27048904
[TBL] [Abstract][Full Text] [Related]
27. Alcohol, the gut microbiome, and liver disease.
Jew MH; Hsu CL
J Gastroenterol Hepatol; 2023 Aug; 38(8):1205-1210. PubMed ID: 37096652
[TBL] [Abstract][Full Text] [Related]
28. Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions.
Rajapakse J; Khatiwada S; Akon AC; Yu KL; Shen S; Zekry A
Gut Microbes; 2023 Dec; 15(2):2240031. PubMed ID: 37615334
[TBL] [Abstract][Full Text] [Related]
29. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.
Lang S; Schnabl B
Cell Host Microbe; 2020 Aug; 28(2):233-244. PubMed ID: 32791115
[TBL] [Abstract][Full Text] [Related]
30. Gut-liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota.
Ohtani N; Hara E
Cancer Sci; 2021 Nov; 112(11):4433-4443. PubMed ID: 34533882
[TBL] [Abstract][Full Text] [Related]
31. The Gut Microbiota: A Novel Player in Autoimmune Hepatitis.
Cheng Z; Yang L; Chu H
Front Cell Infect Microbiol; 2022; 12():947382. PubMed ID: 35899041
[TBL] [Abstract][Full Text] [Related]
32. Gut non-bacterial microbiota contributing to alcohol-associated liver disease.
Gao W; Zhu Y; Ye J; Chu H
Gut Microbes; 2021; 13(1):1984122. PubMed ID: 34711112
[TBL] [Abstract][Full Text] [Related]
33. Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression.
Mungamuri SK; Vijayasarathy K
Crit Rev Oncog; 2020; 25(1):57-70. PubMed ID: 32865911
[TBL] [Abstract][Full Text] [Related]
34. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
Chen YH; Wu WK; Wu MS
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
[TBL] [Abstract][Full Text] [Related]
35. Microbiota reprogramming for treatment of alcohol-related liver disease.
Siddiqui MT; Cresci GAM
Transl Res; 2020 Dec; 226():26-38. PubMed ID: 32687975
[TBL] [Abstract][Full Text] [Related]
36. Impacts of gut microbiota alteration on age-related chronic liver diseases.
Adhikary S; Esmeeta A; Dey A; Banerjee A; Saha B; Gopan P; Duttaroy AK; Pathak S
Dig Liver Dis; 2024 Jan; 56(1):112-122. PubMed ID: 37407321
[TBL] [Abstract][Full Text] [Related]
37. Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma.
Song Y; Lau HC; Zhang X; Yu J
Cancer Biol Med; 2023 Dec; 21(2):144-62. PubMed ID: 38148326
[TBL] [Abstract][Full Text] [Related]
38. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
39. The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases.
An L; Wirth U; Koch D; Schirren M; Drefs M; Koliogiannis D; Nieß H; Andrassy J; Guba M; Bazhin AV; Werner J; Kühn F
J Gastrointest Surg; 2022 Mar; 26(3):671-683. PubMed ID: 34734369
[TBL] [Abstract][Full Text] [Related]
40. NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota.
Lu X; Yang R; Chen Y; Chen D
iScience; 2024 Mar; 27(3):109174. PubMed ID: 38405608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
